Overview

Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies

Status:
Active, not recruiting

Trial end date:
2023-06-09

Target enrollment:

Participant gender:

Summary

The purpose of this study is to allow continued use of pasireotide in patients who are on pasireotide treatment in a Novartis-sponsored study and are benefiting from the treatment as judged by the investigator.

Phase:

Phase 4

Details

Lead Sponsor:

Novartis Pharmaceuticals
RECORDATI GROUP

Treatments:

Cabergoline
Pasireotide
Somatostatin